Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Aug 30;12(8):e10143.
doi: 10.7759/cureus.10143.

Efficacy and Safety of Direct Oral Anticoagulant for Treatment of Atrial Fibrillation in Cerebral Amyloid Angiopathy

Affiliations
Case Reports

Efficacy and Safety of Direct Oral Anticoagulant for Treatment of Atrial Fibrillation in Cerebral Amyloid Angiopathy

Koichi Narita et al. Cureus. .

Abstract

A 75-year-old man with a history of atrial fibrillation (AF) and anticoagulant therapy presented with a headache. Cerebral amyloid angiopathy (CAA) was diagnosed after MRI of the brain revealed cortical superficial siderosis, lobar intracerebral hemorrhage, and lobar microbleeds. Anticoagulant therapy was carefully discontinued. Several years later, he was admitted with sudden onset left upper-extremity weakness. In addition to CAA bleeding lesions, a diffusion-weighted brain MRI showed multiple infarct lesions of high signal intensity. The administration of edoxaban 7.5 mg/day (later increased up to 30 mg/day) prevented ischemic stroke recurrence without exacerbation of cerebral bleeding. This could indicate that CAA patients with AF who had previous adverse effects from warfarin can safely use newer direct oral anticoagulants, such as edoxaban, to prevent ischemic stroke without danger of cerebral hemorrhage. The superiority of edoxaban as compared with warfarin might be due to its antioxidant effect because vascular oxidative stress plays a causal role in CAA-induced cerebrovascular dysfunction, CAA-induced cerebral hemorrhage, and CAA formation itself. We explained the beneficial effect of edoxaban for CAA by the mechanism of oxidative stress in the paper.

Keywords: anticoagulant therapy; atrial fibrillation; cerebral amyloid angiopathy; direct oral anticoagulant; oxidative stress.

PubMed Disclaimer

Conflict of interest statement

EA belongs to the Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, University of Tokyo, which is endowed by Actelion Pharmaceuticals Japan Ltd., Otsuka Pharmaceutical, NIPRO CORPORATION, Terumo Corp., Senko Medical Instrument Mfg., Century Medical Inc., Kinetic Concepts Inc., and St. Jude Medical.

Figures

Figure 1
Figure 1. Summary of the progress of this case
A: T1-weighted image (T1WI) sequence showing a hypodensity lesion in the right putamen. B: Axial fluid-attenuated inversion recovery (FLAIR) sequences showing an isodensity with 7 mm at the same lesion with A, which suggested old cerebral bleeding. C: T2WI sequence showing hemosiderosis in the left frontal lobe. D: T2*WI sequence showing a low-intensity lesion in the left frontal lobe. E: T1WI sequence showing high intensities in the same lesion as D, in the left frontal lobe, which suggests subacute cerebral hemorrhage. F: Cerebral CT showing left cerebellar infarction. G, H: Diffusion-weighted image (DWI) sequence showing multiple deep and cortical infarct lesions, including right central groove lesion. I: DWI sequence showing recurrence of cerebral infarction in other sites. J: Time course of the level of D-dimer and medical treatment about anticoagulation.

Similar articles

References

    1. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE) Lip GYH, Collet JP, de Caterina R, et al. Europace. 2017;19:1757–1758. - PubMed
    1. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. January CT, Wann LS, Calkins H, et al. J Am Coll Cardiol. 2019;74:104–132. - PubMed
    1. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Hart RG, Tonarelli SB, Pearce LA. Stroke. 2005;36:1588–1593. - PubMed
    1. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: a prospective, multicenter, observational study. Toyoda K, Yasaka M, Iwade K, et al. Stroke. 2008;39:1740–1745. - PubMed
    1. Review: sporadic cerebral amyloid angiopathy. Attems J, Jellinger K, Thal DR, Van Nostrand W. https://pubmed.ncbi.nlm.nih.gov/20946241/#:~:text=Cerebral%20amyloid%20a... Neuropathol Appl Neurobiol. 2011;37:75–93. - PubMed

Publication types

LinkOut - more resources